RT Journal Article
SR Electronic
T1 Post-COVID syndrome prevalence and risk factors in children and adolescents: A population-based serological study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.24.22279150
DO 10.1101/2022.08.24.22279150
A1 Dumont, Roxane
A1 Richard, Viviane
A1 Lorthe, Elsa
A1 Loizeau, Andrea
A1 Pennacchio, Francesco
A1 Zaballa, María-Eugenia
A1 Baysson, Hélène
A1 Nehme, Mayssam
A1 Perrin, Anne
A1 L’Huillier, Arnaud G.
A1 Kaiser, Laurent
A1 Barbe, Rémy P.
A1 Posfay-Barbe, Klara M.
A1 Stringhini, Silvia
A1 Guessous, Idris
A1 the SEROCoV-KIDS study group
YR 2022
UL http://medrxiv.org/content/early/2022/08/24/2022.08.24.22279150.abstract
AB Objectives Post-COVID syndrome remain poorly studied in children and adolescents. In this study, we aimed to investigate the prevalence and risk factors of pediatric post-COVID in a population-based sample, stratifying by serological status.Study design We used data from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), which included children (aged 6 months to 17 years) selected from random samples drawn from state registries or who had a household member participating in a COVID-19 seroprevalence study conducted by our group. Children were tested for anti-SARS-CoV-2 N antibodies. Parents filled in a questionnaire on persistent symptoms in their children (lasting over 12 weeks) compatible with post-COVID syndrome.Results From December 1st, 2021 to February 16th, 2022, 1034 children were included, among whom 570 (55.1%) were seropositive. The sex- and age-adjusted prevalence of persistent symptoms among seropositive children was 9.1% (95%CI: 6.7;11.8) and 5.0% (95%CI: 3.0;7.1) among seronegatives, with an adjusted prevalence difference (ΔaPrev) of 4.1% (95%CI: 1.1;7.3). After stratification by age group, the prevalence was higher among adolescents aged 12-17 years (ΔaPrev=8.3%, 95%CI: 3.5;13.5) than among younger children (0.0%, 95%CI: −5.2;5.2 among 6-11 years old and 4.2%; 95%CI: −4.4;13.3 among 0-5 years old). The most frequently declared persistent symptoms among seropositives were smell loss, trouble concentrating and abdominal pain. Older age, having a chronic condition and lower socioeconomic conditions were identified as risk factors.Conclusion A significant proportion of seropositive children, particularly adolescents, experienced persistent symptoms. While there is a need for further investigation, growing evidence of pediatric post-COVID syndrome urges early screening and primary care management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFundings The project is partially funded by the Jacobs Foundation, and partially funded by the FOPH. The Jacobs Foundation and the FOPH are supporting the project for a 36 and 18 months, respectively. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Geneva Cantonal Commission for Research Ethics approved this study (ID 2021-01973).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data are accessible to researchers upon reasonable request for data sharing to the corresponding author. ΔaPrevadjusted Prevalence DifferenceaPrevadjusted PrevalenceaPRadjusted Prevalence RatioCIConfidence intervalCOVID-19Coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2